Figure 3
Cumulative risk of the primary safety outcomes of life-threatening (including fatal) or disabling or major bleeding events [Bleeding Academic Research Consortium (BARC) 4, 3a, 3b, and 3c], as defined by the Valve Academic Research Consortium-2 (VARC-2) in the whole population (A) and according to the need (B, Stratum 1) or not (C, Stratum 2) for chronic oral anticoagulation in the safety population.

Cumulative risk of the primary safety outcomes of life-threatening (including fatal) or disabling or major bleeding events [Bleeding Academic Research Consortium (BARC) 4, 3a, 3b, and 3c], as defined by the Valve Academic Research Consortium-2 (VARC-2) in the whole population (A) and according to the need (B, Stratum 1) or not (C, Stratum 2) for chronic oral anticoagulation in the safety population.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close